Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | METAP1 | P53582 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30025550 | 0.84 | ADRA2A (0.34) | ADRA2APARP10PARP1HTR5AALDH1A1 | |
| SCHEMBL7938077 | 0.84 | ADRA2A (0.34) | ADRA2APARP10PARP1HTR5AALDH1A1 | |
| Hydrochloric Acid SCHEMBL11820690 | 0.82 | ADRA2A (0.33) | ADRA2APARP10HTR5AALDH1A1CYP1A2 | |
| SCHEMBL9573156 | 0.80 | HTR2A (0.38) | ADRA2APARP10PARP1HTR5AMETAP1 | |
| SCHEMBL29991918 | 0.80 | HTR2A (0.38) | ADRA2APARP10PARP1HTR5AMETAP1 | |
| SCHEMBL7934799 | 0.79 | HTR5A (0.38) | ADRA2APARP10PARP1CYP19A1CYP11B2 | |
| Hydrochloric Acid SCHEMBL11649289 | 0.78 | HTR2A (0.37) | ADRA2APARP10PARP1HTR5AMETAP1 | |
| SCHEMBL28293542 | 0.77 | — | — | |
| SCHEMBL23348757 | 0.76 | PBRM1 (0.37) | — | |
| SCHEMBL9572969 | 0.76 | ADRA2A (0.39) | ADRA2APARP10PARP1HTR5AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-115626889-A | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2023-01-20 | — | — | CN | disclosed |
| EP-3719099-A1 | PHOSPHORESCENT MATERIALS | Universal Display Corporation (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3351247-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | Auspex Pharmaceutical, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3327100-A2 | PHOSPHORESCENT MATERIALS | Universal Display Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2489716-B1 | Phosphorescent materials | UNIVERSAL DISPLAY CORP (US) | 2017-12-27 | — | — | EP | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| EP-1973909-A2 | TRANSFORMING GROWTH FACTOR MODULATORS | Biogen Idec MA Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007076127-A2 | CONDENSED IMIDAZOLES OR PYRAZOLES AND THEIR USE AS TRANSFORMING GROWTH FACTOR MODULATORS | BIOGEN IDEC MA INC (US) | 2007-07-05 | — | — | WO | disclosed |
| CN-1875003-A | Process for producing dihydroisoquinoline zwitterions and organic catalyst | PROCTER & GAMBLE (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1680404-A1 | PROCESS FOR PRODUCING DIHYDROISOQUINOLINE ZWITTERIONS | The Procter & Gamble Company (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050113246-A1 | Process of producing an organic catalyst | THE PROCTER & GAMBLE COMPANY | 2005-05-26 | — | — | US | disclosed |
| WO-2005047264-A1 | PROCESS FOR PRODUCING DIHYDROISOQUINOLINE ZWITTERIONS | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-5231181-A | PROCESS FOR THE PREPARATION OF (8AS,12AS,13AS)-DECAHYDROISOQUINO ((2,1-G) (1,6)-NAPHTHYRIDIN-8-ONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1993-07-27 | — | — | US | disclosed |
| US-5229387-A | Cardiovascular disorders, alpha2-adenoreceptor antagonist or hydroxytryptamine receivers as hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0524004-A1 | Decahydro-8H-isoquino[2,1-g][1,6]naphthyridine and decahydrobenzo[a]pyrrolo[2,3-e]quinolizine derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0505183-A2 | Process for the preparation of (8aS,12aS,13aS)-decahydroisoquino[2,1-g][1,6]-naphthyridin-8-one derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | STAT3, JAK2, STAT6 | ADRA2A 4563/4885PARP10 1502/4885PARP1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.